VIANIQ Holdings Ltd has made significant updates regarding its business combination with Mountain Crest Acquisition Corp. V, as detailed in a recent prospectus supplement filed on November 2, 2026. This filing is crucial as it reflects the company's new identity following its name change from CubeBio Holdings Limited. The update is part of a strategic effort to enhance its presence in the surgical and medical instruments sector.

VIANIQ Holdings, classified under the SIC code 3841, specializes in surgical and medical instruments and apparatus. The company is an emerging growth entity and trades under the ticker symbol KUBE. The recent filings indicate an active engagement with shareholders and stakeholders, particularly as it prepares for its upcoming business combination.

The latest filing, a prospectus supplement, serves to update and supplement the information provided in the proxy statement/prospectus dated October 19, 2026. It specifically incorporates details from a Form 6-K submitted to the SEC on October 30, 2026. This prospectus supplement is essential for investors and stakeholders as it provides clarity on the company's direction and operational updates.

According to the filing, the change of name was officially approved by the sole shareholder on October 20, 2026, and the Registrar of Companies in the Cayman Islands issued a Certificate of Incorporation on Change of Name on October 21, 2026. VIANIQ Holdings Limited aims to maintain continuity in its business operations despite the rebranding. The filing states, "The change of name does not affect the terms of the proposed Business Combination with Mountain Crest Acquisition Corp. V." This continuity is vital for investor confidence and market stability.

The filing also mentions that VIANIQ intends to apply for its ordinary shares to be listed on Nasdaq under the symbol “VIAN” in connection with the closing of the business combination. However, it cautions that there is no guarantee of approval for the listing. This step is significant as it could enhance the company's visibility and access to capital markets.

Investors and stakeholders in the surgical and medical instruments industry may be particularly interested in this update, as it signals VIANIQ's commitment to growth and transparency in its operations. The company’s strategic moves may influence competitive dynamics within the sector, as it seeks to establish itself as a key player.

Looking ahead, the filing does not specify any immediate next steps beyond the ongoing business combination process. However, stakeholders can expect further updates as VIANIQ progresses with its plans and responds to market conditions.